Bigner DD - Search Results

1

Marshall D, Mitchell DA, Graner MW, Bigner DD. Marshall D, et al. Among authors: bigner dd. Handb Clin Neurol. 2012;104:309-30. doi: 10.1016/B978-0-444-52138-5.00020-7. Handb Clin Neurol. 2012. PMID: 22230450 Review. No abstract available.

2

Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors.

Chandramohan V, Mitchell DA, Johnson LA, Sampson JH, Bigner DD. Chandramohan V, et al. Among authors: bigner dd. Future Oncol. 2013 Jul;9(7):977-90. doi: 10.2217/fon.13.47. Future Oncol. 2013. PMID: 23837761 Free PMC article. Review.

3

The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors.

Fecci PE, Mitchell DA, Archer GE, Morse MA, Lyerly HK, Bigner DD, Sampson JH. Fecci PE, et al. Among authors: bigner dd. J Neurooncol. 2003 Aug-Sep;64(1-2):161-76. doi: 10.1007/BF02700031. J Neurooncol. 2003. PMID: 12952297 Review.

4

Chaperone proteins and brain tumors: potential targets and possible therapeutics.

Graner MW, Bigner DD. Graner MW, et al. Among authors: bigner dd. Neuro Oncol. 2005 Jul;7(3):260-78. doi: 10.1215/S1152851704001188. Neuro Oncol. 2005. PMID: 16053701 Free PMC article. Review.

5

Therapeutic aspects of chaperones/heat-shock proteins in neuro-oncology.

Graner MW, Bigner DD. Graner MW, et al. Among authors: bigner dd. Expert Rev Anticancer Ther. 2006 May;6(5):679-95. doi: 10.1586/14737140.6.5.679. Expert Rev Anticancer Ther. 2006. PMID: 16759160 Review.

6

Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.

Fecci PE, Sweeney AE, Grossi PM, Nair SK, Learn CA, Mitchell DA, Cui X, Cummings TJ, Bigner DD, Gilboa E, Sampson JH. Fecci PE, et al. Among authors: bigner dd. Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4294-305. doi: 10.1158/1078-0432.CCR-06-0053. Clin Cancer Res. 2006. PMID: 16857805

7

The heat shock response and chaperones/heat shock proteins in brain tumors: surface expression, release, and possible immune consequences.

Graner MW, Cumming RI, Bigner DD. Graner MW, et al. Among authors: bigner dd. J Neurosci. 2007 Oct 17;27(42):11214-27. doi: 10.1523/JNEUROSCI.3588-07.2007. J Neurosci. 2007. PMID: 17942716 Free PMC article.

8

Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.

Everson RG, Graner MW, Gromeier M, Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS, Friedman AH, Bigner DD, Sampson JH. Everson RG, et al. Among authors: bigner dd. Expert Rev Anticancer Ther. 2008 May;8(5):717-32. doi: 10.1586/14737140.8.5.717. Expert Rev Anticancer Ther. 2008. PMID: 18471045 Review.

9

Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.

Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Bigner DD. Sampson JH, et al. Among authors: bigner dd. Semin Immunol. 2008 Oct;20(5):267-75. doi: 10.1016/j.smim.2008.04.001. Epub 2008 Jun 9. Semin Immunol. 2008. PMID: 18539480 Free PMC article. Review.

10

Proteomic and immunologic analyses of brain tumor exosomes.

Graner MW, Alzate O, Dechkovskaia AM, Keene JD, Sampson JH, Mitchell DA, Bigner DD. Graner MW, et al. Among authors: bigner dd. FASEB J. 2009 May;23(5):1541-57. doi: 10.1096/fj.08-122184. Epub 2008 Dec 24. FASEB J. 2009. PMID: 19109410 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

630 results

Search Page